ANDA 216859, held by Mankind Pharma. Phenylephrine Hydrochloride.
As of Nov 16, 2026, ANDA 216859 (Phenylephrine Hydrochloride), held by Mankind Pharma, was first approved by FDA on Sep 29, 2022, with 1 approved supplement and 0 published complete response letters.
Phenylephrine Hydrochloride Ophthalmic Solution 2.5%, is indicated to dilate the pupil. Phenylephrine Hydrochloride Ophthalmic Solution is an alpha-1 adrenergic receptor agonist indicated to dilate the pupil
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 29, 2022 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Phenylephrine Hydrochloride2.5% · solution/drops;ophthalmic | Phenylephrine Hydrochloride | Rx |
| Mar 15, 2023 | Supplement 1Manufacturing | Approved | None posted |
| Sep 29, 2022 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters